Local Delivery of Protease-Resistant Stromal Cell Derived Factor-1 for Stem Cell Recruitment After Myocardial Infarction

Background— Local delivery of chemotactic factors represents a novel approach to tissue regeneration. However, successful chemokine protein delivery is challenged by barriers including the rapid diffusion of chemokines and cleavage of chemokines by proteases that are activated in injured tissues. Stromal cell–derived factor-1 (SDF-1) is a well-characterized chemokine for attracting stem cells and thus a strong candidate for promoting regeneration. However, SDF-1 is cleaved by exopeptidases and matrix metalloproteinase-2, generating a neurotoxin implicated in some forms of dementia. Methods and Results— We designed a new chemokine called S-SDF-1(S4V) that is resistant to matrix metalloproteinase-2 and exopeptidase cleavage but retains chemotactic bioactivity, reducing the neurotoxic potential of native SDF-1. To deliver S-SDF-1(S4V), we expressed and purified fusion proteins to tether the chemokine to self-assembling peptides, which form nanofibers and allow local delivery. Intramyocardial delivery of S-SDF-1(S4V) after myocardial infarction recruited CXCR4+/c-Kit+ stem cells (46±7 to 119±18 cells per section) and increased capillary density (from 169±42 to 283±27 per 1 mm2). Furthermore, in a randomized, blinded study of 176 rats with myocardial infarction, nanofiber delivery of the protease-resistant S-SDF-1(S4V) improved cardiac function (ejection fraction increased from 34.0±2.5% to 50.7±3.1%), whereas native SDF-1 had no beneficial effects. Conclusions— The combined advances of a new, protease-resistant SDF-1 and nanofiber-mediated delivery promoted recruitment of stem cells and improved cardiac function after myocardial infarction. These data demonstrate that driving chemotaxis of stem cells by local chemokine delivery is a promising new strategy for tissue regeneration.

[1]  J. Isner,et al.  Stromal Cell–Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization , 2003, Circulation.

[2]  E. Chavakis,et al.  Differentiation of circulating endothelial progenitor cells to a cardiomyogenic phenotype depends on E‐cadherin , 2005, FEBS letters.

[3]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[4]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[5]  H. Birkedal‐Hansen,et al.  Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). , 1993, Biochemistry.

[6]  C. Overall,et al.  Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.

[7]  M. Hollenberg,et al.  Proteolytic processing of SDF-1α reveals a change in receptor specificity mediating HIV-associated neurodegeneration , 2006, Proceedings of the National Academy of Sciences.

[8]  Sriram Neelamegham,et al.  An analysis tool to quantify the efficiency of cell tethering and firm-adhesion in the parallel-plate flow chamber. , 2003, Journal of immunological methods.

[9]  J. Bryant,et al.  Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. , 2000, Cardiovascular research.

[10]  S. Rafii,et al.  Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector‐Mediated Elevation of Serum Levels of SDF‐1, VEGF, and Angiopoietin‐1 , 2001, Annals of the New York Academy of Sciences.

[11]  Eric J Topol,et al.  Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy , 2003, The Lancet.

[12]  Stefanie Dimmeler,et al.  Transdifferentiation of Blood-Derived Human Adult Endothelial Progenitor Cells Into Functionally Active Cardiomyocytes , 2003, Circulation.

[13]  G. Opdenakker,et al.  Chemokine-protease interactions in cancer. , 2004, Seminars in cancer biology.

[14]  Fuquan Yang,et al.  Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. , 2004, Blood.

[15]  C. Overall,et al.  HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration , 2003, Nature Neuroscience.

[16]  Yan Huang,et al.  Stromal Cell–Derived Factor-1α Plays a Critical Role in Stem Cell Recruitment to the Heart After Myocardial Infarction but Is Not Sufficient to Induce Homing in the Absence of Injury , 2004, Circulation.

[17]  S. Nishikawa,et al.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.

[18]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[19]  R. Wong,et al.  Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. , 2006, Biochemical pharmacology.

[20]  L. Villeneuve,et al.  Antagonism of stromal cell-derived factor-1α reduces infarct size and improves ventricular function after myocardial infarction , 2007, Pflügers Archiv - European Journal of Physiology.

[21]  M. Madlener.  Differential expression of matrix metalloproteinases and their physiological inhibitors in acute murine skin wounds , 1998, Archives of Dermatological Research.

[22]  E. Deroubaix,et al.  Structural Localization and Expression of CXCL12 and CXCR4 in Rat Heart and Isolated Cardiac Myocytes , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  Richard T. Lee,et al.  Local delivery of proteins and the use of self-assembling peptides. , 2007, Drug discovery today.

[24]  David A. Davis,et al.  Differential processing of stromal-derived factor-1α and stromal-derived factor-1β explains functional diversity , 2004 .

[25]  A. Rich,et al.  Self-complementary oligopeptide matrices support mammalian cell attachment. , 1995, Biomaterials.